Languages: English, Bengali, Hindi
Allogeneic Bone Marrow Transplantation, Lymphoma, Oncology ...read more
T-cell Lymphomas; T-cell Acute Lymphoblastic Leukemias; CAR T Cell Therapy; Bispecific Antibody Therapy ...read more
I am a physician-scientist in the Division of Hematological Malignancies and stem cell transplantation at the Sidney Kimmel Comprehensive Cancer Center, where I specialize in the treatment of lymphomas. My primary research focuses on developing new biologic therapies for the treatment of T-cell lymphomas and T-cell leukemias.
Lab Website: Suman Paul Laboratory
Paul S, Kashyap AK, Jia W, He YW, Schaefer BC. Selective Autophagy of the Adaptor Protein Bcl10 Modulates T Cell Receptor Activation of NF-κB. Immunity 2012 Jun. PMID: 22658522
Paul S, Traver MK, Kashyap AK, Washington MA, Latoche JR, Schaefer BC. T Cell Receptor Signals to NF-κB are Transmitted by a Cytosolic p62-Bcl10-Malt1-IKK Signalosome. Science Signaling 2014 May. PMID: 24825920
Paul S, Tsai HL, Fuchs EJ, Luznik L, Bolaños-Meade J, Swinnen LJ, Shanbhag S, Wagner-Johnston N, Varadhan R, Ambinder RF, Jones RJ, Gladstone DE. Allogeneic Haploidentical Blood or Marrow Transplantation with Post-Transplant Cyclophosphamide in Chronic Lymphocytic Leukemia. Biology of Blood and Marrow Transplantation. 2019 Nov. PMID: 31730920
Paul S, Zahurak M, Fuchs EJ, Luznik L, Bolaños-Meade J, Swinnen LJ, Shanbhag S, Wagner-Johnston N, Varadhan R, Ambinder RF, Jones RJ, Gladstone DE. Non-Myeloablative Allogeneic Transplantation with Post-Transplant Cyclophosphamide after Immune Checkpoint Inhibition for Classic Hodgkin Lymphoma: a Retrospective Cohort Study. Biology of Blood and Marrow Transplantation. 2020 June. PMID: 32592857
Paul S, Pearlman A, Douglass J, Mog BJ, Hsiue EH, Hwang MS, DiNapoli S, Konig MF, Brown P, Wright KM, Gabelli SB, Li Y, Ghiaur G, Pardoll DM, Papadopoulos N, Bettegowda C, Kinzler KW, Zhou S, Vogelstein B. TCR beta chain-directed bispecific antibodies for the treatment of T-cell cancer. Science Translational Medicine. 2021 March. PMID: 33649188
Methods and materials for treating t cell cancers
Patent # 63/119,753, |
TRBC1 and TRBC2 bispecific antibodies for targeting T-cell cancers
Patent # 63/150,232 |
Researchers Create Modified Antibodies to Target RAS and p53 in Cancer, Cancer.gov (April 2, 2021)
Mutant Gene-Targeted Immunotherapy Approach Developed, Brookhaven National Laboratory (April 2, 2021)
Advances in Off-the-Shelf Immunotherapy: Expert Discussion, Oncology Times (October 5, 2021)
First soluble TCR therapy opens ‘new universe’ of cancer targets. Nature Biotechnology (March 24, 2022)
Leukemia Lymphoma Society award recipient, Leukemia & Lymphoma Society
Patient Ratings & Comments
The Patient Rating score is an average of all responses to physician related questions on the national CG-CAHPS Medical Practice patient experience survey through Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are also gathered from our CG-CAHPS Medical Practice Survey through Press Ganey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.